Izeta A, Sanchez C M, Smerdou C, Mendez A, Alonso S, Balasch M, Plana-Durán J, Enjuanes L
Department of Molecular and Cell Biology, Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
Adv Exp Med Biol. 1998;440:207-14. doi: 10.1007/978-1-4615-5331-1_25.
The minimum sequence required for the replication and packaging of transmissible gastroenteritis virus (TGEV)-derived minigenomes has been determined. To this end, cDNAs encoding defective RNAs have been cloned and used to express heterologous spike proteins, to determine the influence of the peplomer protein in the control of TGEV tropism. A TGEV defective interfering RNA of 9.7 kb (DI-C) was isolated, and a cDNA complementary to DI-C RNA was cloned under the control of T7 promoter. In vitro transcribed DI-C RNA was replicated in trans upon transfection of helper virus-infected cells. A collection of DI-C deletion mutants (TGEV minigenomes) was generated and tested for their ability to be replicated and packaged. The size of the smallest minigenome replicated in trans was 3.3 kb. The rescue system was used to express the spike protein of an enteric TGEV isolate (C11) using as helper virus a TGEV strain (C8) that replicates very little in the gut. A mixture of two pseudorecombinant viruses containing either the helper virus genome or the minigenome was obtained. These pseudorecombinants display in the surface the S proteins from the enteric and the attenuated virus, and showed 10(4)-fold increase in their gut replication levels as compared to the helper isolate (C8). In addition, the pseudorecombinant virus increased its enteric pathogenicity as compared to the C8 isolate.
已确定了可传播性胃肠炎病毒(TGEV)衍生的微型基因组进行复制和包装所需的最小序列。为此,编码缺陷RNA的cDNA已被克隆,并用于表达异源刺突蛋白,以确定纤突蛋白在控制TGEV嗜性方面的影响。分离出一种9.7 kb的TGEV缺陷干扰RNA(DI-C),并在T7启动子的控制下克隆了与DI-C RNA互补的cDNA。体外转录的DI-C RNA在辅助病毒感染的细胞转染后可进行反式复制。构建了一系列DI-C缺失突变体(TGEV微型基因组),并测试了它们的复制和包装能力。反式复制的最小微型基因组大小为3.3 kb。利用该拯救系统,以在肠道中复制能力极低的TGEV毒株(C8)作为辅助病毒,表达肠道TGEV分离株(C11)的刺突蛋白。获得了两种假重组病毒的混合物,其中一种含有辅助病毒基因组,另一种含有微型基因组。这些假重组病毒在表面展示了来自肠道病毒和减毒病毒的S蛋白,并且与辅助分离株(C8)相比,其在肠道中的复制水平提高了10^4倍。此外,与C8分离株相比,假重组病毒的肠道致病性增强。